Hidrocortizon Panpharma (Hydrocortisone)

Hidrocortizon Panpharma is employed when a rapid, systemic glucocorticoid effect is needed, such as in emergency or acute care settings.

• Replacement therapy for primary or secondary adrenal insufficiency, including Addison’s disease, to maintain cortisol levels.
• Management of acute severe allergic reactions, such as anaphylaxis, to rapidly reduce airway edema and hypotension.
• Treatment of asthma or chronic obstructive pulmonary disease exacerbations that require systemic steroids for bronchodilation and inflammation control.
• Adjunctive therapy for septic shock or severe systemic inflammation to support hemodynamic stability and modulate cytokine release.
• Short‑term control of postoperative or traumatic inflammatory responses, helping to limit swelling and pain.

• Hydrocortisone acts as an agonist at intracellular glucocorticoid receptors. After diffusing into cells, the drug‑receptor complex translocates to the nucleus, where it binds glucocorticoid response elements on DNA, modulating transcription of anti‑inflammatory proteins such as annexin‑1 and suppressing pro‑inflammatory cytokines like interleukin‑1, interleukin‑6, and tumor necrosis factor‑α. This genomic effect reduces vascular permeability, leukocyte migration, and overall systemic immune responses.

Adverse reactions to Hidrocortizon Panpharma can vary from mild and transient to rare but serious events.

Common

• Transient elevation of blood glucose levels, especially in diabetic patients.
• Fluid retention leading to mild peripheral edema.
• Gastrointestinal discomfort, headache, or insomnia.
• Mild mood changes such as irritability or euphoria.
• Transient increase in blood pressure.
• Mild electrolyte disturbances such as mild hypokalemia.

Serious

• Suppression of the hypothalamic‑pituitary‑adrenal axis causing adrenal insufficiency.
• Severe infections or sepsis due to immunosuppression.
• Allergic reactions ranging from rash to anaphylaxis.
• Cushingoid appearance with weight gain and facial rounding.
• Osteonecrosis of bone with prolonged use.
• Severe hypertension resistant to standard therapy.

When prescribing Hidrocortizon Panpharma, clinicians should consider several precautionary measures to minimize risk.

• Assess baseline cortisol production in patients with known adrenal disorders before initiating therapy.
• Use the lowest effective dose for the shortest duration to reduce systemic effects.
• Monitor blood glucose and electrolytes regularly, especially in diabetic or hypertensive patients.
• Exercise caution in patients with active infections, as immunosuppression may worsen the condition.
• Avoid abrupt discontinuation after prolonged therapy to prevent adrenal crisis; taper gradually under medical guidance.
• Consider potential effects on wound healing; monitor surgical sites for delayed closure.

Hydrocortisone may interact with other medicines, altering its efficacy or increasing the risk of adverse events.

Avoid

• Concurrent use with potent CYP3A4 inducers (e.g., rifampin, phenytoin) which may reduce hydrocortisone plasma levels.
• Co‑administration with systemic antifungal agents that inhibit CYP3A4 (e.g., ketoconazole) which can increase glucocorticoid exposure.
• Concurrent use with high‑dose aspirin may increase risk of bleeding.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may increase the risk of gastrointestinal ulceration.
• Anticoagulants (e.g., warfarin) as glucocorticoids can enhance anticoagulant effects.
• Vaccines, particularly live attenuated vaccines, because immunosuppression may diminish vaccine efficacy.
• Diuretics may potentiate hypokalemia when combined with glucocorticoid‑induced potassium loss.